SCHEMBL25613035

SCHEMBL25613035

CC(C)(C)c1cc2cc[nH]c2nc1OCC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 6/20 0.39
▸ FEN1 P39748 1/20 0.39
▸ FGFR1 P11362 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ CNR2 P34972 1/20 0.34
▸ MAP4K1 Q92918 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CDK8 P49336 3/20 0.34
▸ TNNI3K Q59H18 1/20 0.34
▸ AAK1 Q2M2I8 1/20 0.33
▸ BRD4 O60885 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613037 0.84 FEN1 (0.39) ULK1FEN1FGFR1KDRCDK8
SCHEMBL25613335 0.83 FEN1 (0.39) ULK1FEN1FGFR1KDRCDK8
SCHEMBL24005744 0.83 CNR2 (0.41) ULK1FGFR1KDRCNR2MEN1
SCHEMBL25613050 0.81 FEN1 (0.39) ULK1FEN1FGFR1KDRCDK8
SCHEMBL25613043 0.81 CDK1 (0.39) ULK1FEN1FGFR1KDRMEN1
SCHEMBL25613045 0.81 ULK1 (0.39) ULK1FEN1FGFR1KDRLMNA
SCHEMBL25613057 0.80 KDM4E (0.39) ULK1FEN1FGFR1KDRLMNA
SCHEMBL25613169 0.79 BRD4 (0.40) ULK1FEN1FGFR1KDRMEN1
SCHEMBL25613047 0.78 KDR (0.39) ULK1FEN1FGFR1KDRLMNA
SCHEMBL25613056 0.78 KDM4E (0.39) FEN1FGFR1KDRLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 ULK1 1303/4885FEN1 1864/4885FGFR1 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback